Sorted By:

Relevance


Increase Coverage and Access to Addiction and Overdose Treatment

PhRMA  |  Policy Paper

Prescription drug abuse and addiction is a complex problem with no single solution. According to the National Institute on Drug Abuse, addiction is a brain disease in which some individuals “are more vulnerable than others to becoming addicted, depending on the interplay between genetic makeup, a...
https://www.phrma.org/policy-paper/increase-coverage-and-access-to-addiction-and-overdose-treatment

Policy Solutions: Addressing Market Distortions

PhRMA  |  Report

A well-functioning market can ensure patient access to innovative medicines without sacrificing investment in future treatments and cures. The market-based U.S. health care system has worked well over time, but more can be done to help it work even better. Addressing distortions would help improv...
https://www.phrma.org/report/policy-solutions-addressing-market-distortions

Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis

PhRMA  |  Policy Paper

Significant progress has been made in recent years in our ability to diagnose and treat rheumatoid arthritis (RA), a devastating autoimmune disease that causes progressive joint deterioration and pain in millions of Americans. Therapeutic advances have transformed the RA treatment paradigm over t...
https://www.phrma.org/policy-paper/recognizing-the-value-of-innovation-in-the-treatment-of-rheumatoid-arthritis

Improve Education and Training Related to Prescription Drug Abuse

PhRMA  |  Policy Paper

A comprehensive approach to public education and prescriber training is a critical component of a comprehensive strategy to combat prescription drug abuse. In order to meaningfully address this public health challenge, enhanced tools are needed to enhance education and training across a range of ...
https://www.phrma.org/policy-paper/improve-education-and-training-related-to-prescription-drug-abuse

Fact Check Friday: Biopharmaceutical company communications with payers

PhRMA  |  Blog Post

Read more about PhRMA’s policy solutions regarding responsible communications with payers here.
http://catalyst.phrma.org/fact-check-friday-biopharmaceutical-company-communications-with-payers

Rheumatoid Arthritis Treatments Continue to Demonstrate Increased Value through Additional Research

PhRMA  |  Fact Sheet

This fact sheet includes new data that reveals broader benefits than anticipated at the time of FDA approval for RA treatments. ...
https://www.phrma.org/fact-sheet/rheumatoid-arthritis-treatments-continue-to-demonstrate-increased-value-through-additional-research

Researching Hepatitis C Medicines: Setbacks and Stepping Stones

PhRMA  |  Policy Paper

These so-called “failures” paved the way for the 12 new medicines approved by the U.S.
https://www.phrma.org/policy-paper/researching-hepatitis-c-medicines-setbacks-and-stepping-stones

PhRMA Comment: Draft Guidance for Industry and Review Staff: Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities

PhRMA  |  Speeches & Communication

The Pharmaceutical Research and Manufacturers of America's comments in response to FDA’s Draft Guidance for Industry and Review Staff entitled “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities/Questions and Answers”. – Questions and Answers, Dock...
https://www.phrma.org

PhRMA Comment: Medical Product Communications That Are Consistent With the FDA-Required Labeling—Questions and Answers

PhRMA  |  Speeches & Communication

PhRMA's comments on the FDA's draft guidance entitled “Medical Product Communications That Are Consistent With the FDA-Required Labeling—Questions and Answers” (“Draft Guidance”)....
https://www.phrma.org

PhRMA Comment: Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products

PhRMA  |  Speeches & Communication

PhRMA's comments in response to FDA’s notification of public hearing about manufacturer communications regarding unapproved uses of approved or cleared medical products (“FDA hearing notice”) and FDA’s Memorandum titled “Public Health Interests and First Amendment Considerations Related to Manufa...
https://www.phrma.org

Survey Finds Variability in MS Treatment Preferences Among Individual Patients, and Among Stakeholder Groups.

PhRMA  |  Fact Sheet

Real Endpoints, LLC (RE), a data analytics firm focusing on assessing and quantifying pharmaceutical value, has just completed an extensive literature review and survey to tease out how different stakeholder groups assess the value of current multiple sclerosis (MS) therapies....
https://www.phrma.org/fact-sheet/survey-finds-variability-in-ms-treatment-preferences-among-individual-patients-and-among-stakeholder-groups

Home Page

PhRMA  |  From PhRMA

The Pharmaceutical Research and Manufacturers of America, PhRMA, represents the country’s leading biopharmaceutical researchers and biotechnology companies....
https://www.phrma.org/

The Power of Medicines

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/the-power-of-medicines

PhRMA Launches New “Share the Savings” Campaign to Urge Payers to Share Negotiated Discounts with Patients  

PhRMA  |  Press Release

  “We need to ensure patients receive more of the benefit of price negotiations between biopharmaceutical companies and payers,” said Stephen J.
https://www.phrma.org/press-release/phrma-launches-new-share-the-savings-campaign-to-urge-payers-to-share-negotiated-discounts-with-patients

Biopharmaceutical Companies’ Personalized Medicine Research Yields Innovative Treatments for Patients

PhRMA  |  Fact Sheet

The last five years have been characterized by increased momentum in personalized medicine. As scientific understanding has grown, and tools and technologies have advanced, more personalized medicines are progressing through development and reaching patients....
https://www.phrma.org

Next Generation Cures: A Policy Discussion

From Hope To Cures  |  From Our Network

As policy leaders and regulators in Washington consider ways to accelerate the drug development process, The Hill is convening a timely and thoughtful conversation on ideas and initiatives that could help spur the growth of new medicines and potential cures for ailing patients.
http://www.fromhopetocures.org/video/next-generation-cures-a-policy-discussion

Regulatory, Legal Uncertainties Are Barriers To Value-Based Agreements For Drugs

PhRMA  |  Report

By tying medicine payment to real-world outcomes, VBAs have the potential to support patients' prompt and affordable access to new, innovative treatments while also addressing payers’ cost concerns.
https://www.phrma.org

Quality Measures Addressing Cancer Care

PhRMA  |  Fact Sheet

Increasingly, payers are using quality measures to assess health outcomes and incentivize high-value care.
https://www.phrma.org

Rheumatoid Arthritis Quality: Current and Future Status

PhRMA  |  Fact Sheet

This ongoing shift has led payers to use quality measures to assess health outcomes and incentivize high-value care.
https://www.phrma.org

Home Page Carousel Test

Access Better Coverage  |  From PhRMA

...
http://www.accessbettercoverage.org/home-page-carousel-test

Biopharmaceutical Industry Pipeline Panel Discussion

PhRMA  |  Video

John Lechleiter, PhD, Chairman, President, and Chief Executive Officer of Eli Lilly and Company and the Chairman of PhRMA joins PhRMA President and CEO John Castellani and Genia Long, Managing Principal, Analysis Group for this Webinar to discuss the future of biopharmaceutical innovation.  ...
https://www.phrma.org/video/biopharmaceutical-industry-pipeline-panel-discussion

Schizophrenia Quality: Current and Future Status

PhRMA  |  Fact Sheet

This ongoing shift has led payers to use quality measures to assess health outcomes and incentivize high-value care.
https://www.phrma.org

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

PhRMA  |  Blog Post

The paper points out, “The legal framework must allow appropriate patient-serving care delivery and payment models that encourage broader collaboration among stakeholders to accelerate ongoing improvements in care quality and patient safety while reducing the rate of cost growth….
http://catalyst.phrma.org/stakeholders-agree-modernize-the-legal-framework-to-support-move-to-value-driven-health-care

Patient-Perspective Value Framework

PhRMA  |  Codes & Guidelines

Avalere and FasterCures partnered to formally launch the Patient-Perspective Value Framework (PPVF) Initiative, to develop a framework that truly incorporates patients’ perspective on value....
https://www.phrma.org

Expanding Access to Opioid and Heroin Overdose Reversal Agents

PhRMA  |  Policy Paper

According to the U.S. Centers for Disease Control and Prevention, the rate of deaths from drug overdoses has increased 137%, including a 200% increase in the rate of overdose deaths involving opioids (opioid pain relievers and heroin), since 2000. Communities across the country are faced with the...
https://www.phrma.org/policy-paper/expanding-access-to-opioid-and-heroin-overdose-reversal-agents

You have reviewed the first 75 results out of 1100. Each page contains 25 results. You're on page 3.

prev 1 2 3 4 5 6 next